—
C+
C+ The full Closelook — membership. Open the C+ overview

Axsome Therapeutics Inc (AXSM) — chart, structure and Closelook read

Home› Indices›
Pick a ticker to load its detail page.

Company snapshot — Axsome Therapeutics Inc

AXSM in five paragraphs: what it makes and sells, where it sits in the Closelook stack, who it is priced against, why we track it, what we watch. Research diary, not advice.

What it does
Axsome Therapeutics is a biopharmaceutical company that develops treatments for central nervous system disorders, based in New York. Its marketed products are Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness in narcolepsy or sleep apnoea, and Symbravo for acute migraine. Its pipeline includes AXS-05 for Alzheimer's agitation, AXS-12 and AXS-14 for conditions such as narcolepsy and fibromyalgia, and a further trial of solriamfetol across several disorders.
Where it sits in the stack
Axsome carries no seat in our Rubin or Halo indices, so it sits outside the diary's build-out stacks; it belongs to the Healthcare sector of the US universe, where it is tracked as a commercial-stage CNS drugmaker rather than as a supplier to any technology layer.
Who it is priced against
Closelook's peer group places it with other scored Healthcare names from the US market, chosen for sharing its sector and country: argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics.
Why Closelook tracks it
Axsome carries a Closelook score, with momentum the strongest of its modules and valuation the weakest; it holds no index seat and has not yet appeared in the diary's editions or quotes.
What the diary watches
The diary watches whether the pipeline readouts, particularly AXS-05 in Alzheimer's agitation, add to the commercial portfolio or remain trial-stage.

Axsome Therapeutics Inc (AXSM) trades on US exchanges, classified under Healthcare.

The Closelook company score reads 38/100 composite (momentum 46, quality 22, valuation 13) across 7 modules — the full breakdown, chart structure and analog history load live above.

Written from the company’s public profile and Closelook’s own readings, 2026-09-17. Descriptive, refreshed with the registry; corrections welcome via the imprint. closelook.net is an investment research diary — market structure, index membership and scores are our own readings, not investment advice. Related: index compare · sector dispersion · scanner.

Signals for this name

Every Closelook reading that exists for AXSM, from the same nightly bakes the boards use. Research diary readings, not advice.

Who it is priced against Biotechnology · US · 8 names with week and year-to-date

Peer group

Biotechnology · US

Names in the same industry from the Closelook universe; scored names rank on their Closelook score, the rest on trend state.

Compared against AXSM on the nightly bakes; the Peers tab ranks the cohort on the Closelook scores where it exists.

Dividends and capital return no distribution in twelve months

Dividends and capital return

What AXSM pays out and buys back — distributions read from the price series, money terms from the filings.

  • Distributions No cash distribution recorded in the price series over the last three years
  • Share count +3.8% in FY2025 94 m USD of stock-based compensation in the year

Per-share amounts are derived from the adjusted price series in the listing currency, so dates sit within days of the ex-date; filing figures come from the fundamentals feed for the last reported fiscal year. An investment diary, not a recommendation.

How it trades on rate days beta 0.10 to TLT · on the worst bond days it fell more than the market

How it trades on rate days

How AXSM has moved when long-dated Treasury yields rise — measured against TLT, the 20+ year Treasury fund.

  • Beta to long bonds, 1 year 0.10 — shows only a loose link to bond moves for every 1% move in TLT (20+ year Treasuries), Axsome Therapeutics Inc moved 0.10% on average · correlation 0.02 · higher than 15% of US names
  • Beta, last 3 months 0.73 more rate-sensitive lately than over the year
  • On the 10 worst bond days −1.18% on average against −0.76% for the S&P 500 the 10 sessions of the past year in which TLT fell most, i.e. long yields rose most
  • Latest of those days −4.75% TLT −1.58% that day 2026-09-23

Daily total returns from the adjusted price series; a TLT down day is a day long yields rose. Beta = the average move of the name for a 1% move in TLT. Past sensitivity, not a forecast. An investment diary, not a recommendation.

Weather around the name 4 macro readings: Money Temperature, Factor regime, Sector × region …

The weather around this name

Macro readings that apply by membership — the regime, the factor tape, the sector cell, the funding backdrop.

  • Money Temperature Composite 60/100 · S&P 500 fund at 66, bullish alignedEight instruments scored on position, momentum, volume, volatility and fragility — the regime every name trades inside. Temperature lab → 2026-09-24
  • Factor regime Momentum leading — risk appetite buildingMomentum against low volatility (SPMO / SPLV): above its 50-day trend, 99th percentile of the window, +10.1% over 20 sessions. Factor regime → 2026-09-24
  • Sector × region Health care in US: +1.0% week · −2.7% month · +9.6% quarter · +11.5% yearThe Sector Engine cell this name lives in, from XLV.US; the 11 × 4 matrix shows where its sector is being bought and where it is being sold. Sector Engine → 2026-09-24
  • Sovereign pressure Index 0.60 · up 0.32 over 21 sessionsG7 long-end yields, 10s30s and the slope — the funding weather for every balance sheet on this site. Sovereign pressure → 2026-09-23

FAQ · from the current data · as of 2026-09-24

Quick answers

What is Axsome Therapeutics Inc (AXSM)?

Axsome Therapeutics Inc trades as AXSM on the US exchange (US) and is classified under Healthcare in the Closelook research universe, as of the registry build of 2026-09-24.

Is AXSM in a Closelook index?

Not currently — Axsome Therapeutics Inc is tracked in the Closelook research universe but is not a constituent of a Closelook functional index as of 2026-09-24.

What is Axsome Therapeutics Inc's Closelook composite score?

38 out of 100, with momentum 46, quality 22 and valuation 13 sub-scores, as of 2026-09-24. Scores are Closelook's own research readings, not ratings or investment advice.

Where does AXSM trade against its moving averages?

Mixed moving-average stack: Trades -10.4% vs the 50-day and -2.5% vs the 200-day average, 25.7% below the 52-week high and +67.8% off the 52-week low. Computed from daily closes. As of 2026-09-23 — a technical state from the nightly Closelook bake, not advice. The Technical tab carries the full row.

What does Axsome Therapeutics Inc do?

Axsome Therapeutics is a biopharmaceutical company that develops treatments for central nervous system disorders, based in New York. Its marketed products are Auvelity for major depressive disorder, Sunosi for excessive daytime sleepiness in narcolepsy or sleep apnoea, and Symbravo for acute migraine. Its pipeline includes AXS-05 for Alzheimer's agitation, AXS-12 and AXS-14 for conditions such as narcolepsy and fibromyalgia, and a further trial of solriamfetol across several disorders. Closelook's peer group places it with other scored Healthcare names from the US market, chosen for sharing its sector and country: argenx, Medpace, BeiGene, Globus Medical, Regeneron, Veeva Systems, Vertex Pharmaceuticals and Corcept Therapeutics.

Where does Axsome Therapeutics Inc sit in the AI build-out?

Axsome carries no seat in our Rubin or Halo indices, so it sits outside the diary's build-out stacks; it belongs to the Healthcare sector of the US universe, where it is tracked as a commercial-stage CNS drugmaker rather than as a supplier to any technology layer. Axsome carries a Closelook score, with momentum the strongest of its modules and valuation the weakest; it holds no index seat and has not yet appeared in the diary's editions or quotes.

Does Axsome Therapeutics Inc pay a dividend?

No cash distribution shows in Axsome Therapeutics Inc’s price series over the last three years. The share count rose 3.8% over the fiscal year. The "Dividends and capital return" block on this page carries the lines.

How does Axsome Therapeutics Inc trade when bond yields rise?

Over the past year Axsome Therapeutics Inc had a beta of 0.10 to TLT, the long-dated Treasury fund — it shows only a loose link to bond moves, higher than 15% of US names. On the 10 sessions in which long bonds fell most it moved −1.18% on average, against −0.76% for the S&P 500. The "How it trades on rate days" block on this page carries the lines.

What does this page show?

A live price chart with SMA overlays and drawing tools for AXSM, performance metrics, index-membership context and the Closelook structure read — an investment research diary view, not investment advice.

Related in the Closelook universe

then Biotechnology. Scored names rank on their Closelook score; names without one rank on trend state — above or below their 50- and 200-day averages — never on a score they do not carry.